Welcome to our dedicated page for Legend Biotech news (Ticker: LEGN), a resource for investors and traders seeking the latest updates and insights on Legend Biotech stock.
Legend Biotech Corporation (NASDAQ: LEGN) generates frequent news as a global cell therapy company focused on CAR‑T treatments for cancer. News coverage for Legend Biotech often centers on CARVYKTI® (ciltacabtagene autoleucel; cilta‑cel), its BCMA‑targeted CAR‑T cell therapy for relapsed or refractory multiple myeloma, as well as updates on its broader pipeline of cell therapy programs.
Investors and observers following LEGN news can expect regular announcements on clinical data from the CARTITUDE program in multiple myeloma, including long‑term progression‑free survival results and analyses of earlier‑line use. Company press releases also highlight presentations at major medical meetings such as the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), and the European Hematology Association (EHA), where Legend Biotech shares outcomes from CARVYKTI and investigational candidates like LUCAR‑G39D, LB2102, and LB1908.
Legend Biotech’s news flow includes regulatory milestones, such as FDA and European Commission label updates for CARVYKTI to incorporate overall survival data and new safety information. The company also reports on manufacturing and infrastructure developments, including expansion of its Raritan, New Jersey cell therapy facility and commercial production in Ghent, Belgium, which are intended to support growing global demand.
Quarterly earnings releases and related Form 6‑K filings provide financial updates on collaboration revenue from CARVYKTI, license revenue from agreements with partners, operating expenses, cash and time deposits, and progress toward profitability. Corporate news items may also cover executive appointments, participation in investor conferences, and strategic priorities outlined at healthcare investment events.
For users tracking LEGN, this news page offers a centralized view of Legend Biotech’s clinical, regulatory, manufacturing, and financial announcements, helping contextualize the company’s evolution in the cell therapy and oncology landscape.
Legend Biotech Corporation (NASDAQ: LEGN) has announced its participation in several upcoming investor conferences. The events include the BMO Biopharma Spotlight Series: Oncology Day on November 9, 2022, and the Cowen 6th Annual IO Next Summit on November 11, 2022, both featuring presentations by CEO Ying Huang, Ph.D. Further conferences will take place in Miami on November 14, London on November 17, and New York on November 29, culminating with the Evercore ISI 5th Annual HealthCONx Conference on November 30, 2022.
Legend Biotech Corporation (NASDAQ: LEGN) announced that seven studies on its CAR-T therapy, ciltacabtagene autoleucel (cilta-cel), have been accepted for presentation at the 64th American Society of Hematology (ASH) Annual Meeting. This includes data on sustained minimal residual disease negativity from the pivotal CARTITUDE-1 study and the first presentation of CARTIFAN-1 study results in heavily pretreated Chinese patients. Presentations will highlight ongoing clinical development and long-term follow-up data, reaffirming the potential of cilta-cel to significantly impact multiple myeloma treatment.
Legend Biotech Corporation (NASDAQ: LEGN) has received approval from Japan’s Ministry of Health for its CAR-T therapy, CARVYKTI™ (ciltacabtagene autoleucel), aimed at treating adults with relapsed or refractory multiple myeloma. This therapy is limited to patients with no history of CAR-positive T cell therapy and those who have undergone three or more treatment lines. The approval is based on promising data from the pivotal CARTITUDE-1 study, where 96.9% of non-Japanese patients showed a response, with 67% achieving a stringent complete response.
Legend Biotech Corporation (NASDAQ: LEGN) will host its in-person and virtual Research & Development Day on October 3, 2022, at 10:00 a.m. ET in New York City. The event aims to provide a comprehensive overview of the company's platforms and pipeline developments from its senior leadership team, including CEO Ying Huang and other key executives. A live webcast will be accessible, with a replay available within 24 hours post-event. Investors can register here.
Legend Biotech Corporation (NASDAQ: LEGN) announced participation in several key investor conferences: Citi's 17th Annual BioPharma Conference on September 7, 2022, Wells Fargo Healthcare Conference on September 8, 2022, and the Morgan Stanley Global Healthcare Conference on September 12, 2022, all featuring CEO Ying Huang, Ph.D. Additionally, the company will attend the Jefferies Cell and Genetic Medicine Summit on September 29-30, 2022. Legend Biotech focuses on developing innovative therapies for life-threatening diseases from its headquarters in Somerset, New Jersey.
Legend Biotech Corporation (NASDAQ: LEGN) reported preliminary, unaudited financial results for the six months ended June 30, 2022. The company anticipates a loss between
Legend Biotech Corporation (NASDAQ: LEGN) announced the appointment of three new directors to its Board: Mr. Tomas Heyman (Class I), Dr. Fangliang "Frank" Zhang (Class II), and Dr. Li Mao (Class III). The Board emphasized that these individuals possess essential skills for executing the company’s long-term strategy. Sally Wang resigned as Chair but will continue as a director. Dr. Zhang has been elected Chairman of the Board. The changes aim to strengthen leadership as the company advances its development of innovative therapies.
Legend Biotech has announced an underwritten public offering of 8,140,000 American Depositary Shares (ADSs) at a price of $43.00 per ADS, aiming for approximately $350 million in total gross proceeds. The underwriters also hold a 30-day option to purchase an additional 1,221,000 ADSs. The offering is expected to close on July 29, 2022, pending customary conditions. Morgan Stanley, J.P. Morgan, Jefferies, and Evercore ISI are leading the offering. The ADSs are being sold under an effective shelf registration statement with the SEC.
Legend Biotech Corporation (NASDAQ: LEGN) plans to offer $250 million of American Depositary Shares (ADSs), each representing two ordinary shares, in an underwritten public offering. The company has also granted underwriters a 30-day option to purchase an additional $37.5 million of ADSs. The offering is subject to market conditions and does not guarantee completion. Morgan Stanley, J.P. Morgan, Jefferies, and Evercore ISI are the joint book-running managers. The ADSs will be offered under a previously filed effective shelf registration statement with the SEC.
Legend Biotech presented updated results from the CARTITUDE clinical program for cilta-cel at the ASCO 2022 meeting, showcasing a sustained 98% overall response rate in relapsed or refractory multiple myeloma patients after 28 months. Median progression-free and overall survival times remain unreached, highlighting long-term efficacy. The CARTITUDE-2 study supports the use of cilta-cel in earlier treatment lines, with 95% of patients achieving a complete response. Adverse events were consistent with previous findings, primarily hematologic.